Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.

Garcia de Lucas MD, Miramontes-González JP, Avilés-Bueno B, Jiménez-Millán AI, Rivas-Ruiz F, Pérez-Belmonte LM

Frontiers in endocrinology16 Sept 2022Cited by 15 (Europe PMC)

PMID36187123PMCIDPMC9523693DOI10.3389/fendo.2022.995646PepBankPUB-36187123

Summary

ObjectivesTo investigate the use of once-weekly semaglutide in a real population of people with type 2 diabetes mellitus (T2DM) in three Spanish hospitals.MethodAn observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting. The primary endpoint was the change in HbA1c from baseline to the end of the study. The secondary endpoints included changes in body weight and the proportion of people with T2DM, achieving HbA1c 5%.ResultsAfter 24 months of follow-up, the reductions in HbA1c were -0.91 ± 0.7% (p<0.001) in the total cohort, -1.13 ± 1.38% (p<0.019) for GLP-1RA-naïve participants, and -0.74 ± 0.9% (p<0.023) for GLP-1RA-experienced participants. Body weight reductions were -12.42 ± 9.1% in GLP-1RA-naïve participants vs. -7.65 ± 9.7% in GLP-1RA-experienced participants (p<0.001). In the total cohort, 77.1% reached the objective of an HbA1c level <7%, and 12.7% reached between 7.1% and 7.5%. Additionally, 66.9% achieved a weight reduction ≥5%. Of all cohort, 90% received 1 mg of semaglutide once a week. The reported adverse events were consistent with the known safety profile of semaglutide.ConclusionsIn routine clinical practice in Spain, the use of semaglutide once a week was associated with statistically significant and clinically relevant improvements in HbA1c and body weight in a wide range of adults with T2DM, without notable adverse effects, which supports real-world use.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, once-weekly semaglutide reduced HbA1c by 0.91% over 24 months in the total cohort.
In plain wordsIn adults with type 2 diabetes, long-term blood sugar fell over 24 months of once-weekly semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change, total cohort
Study
n = 166
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
HbA1c change
−0.91%
total cohort
Source sentences
Summary
After 24 months of follow-up, the reductions in HbA1c were -0.91 ± 0.7% (p<0.001) in the total cohort, -1.13 ± 1.38% (p<0.019) for GLP-1RA-naïve participants, and -0.74 ± 0.9% (p<0.023) for GLP-1RA-experienced participants.
1 context sentence(design, population, supporting numbers)
Summary · context
An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting.
Show in the study text Report a problemFND-3618712301
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes who switched from another GLP-1 receptor agonist, once-weekly semaglutide reduced HbA1c by 0.74% over 24 months.
In plain wordsIn adults with type 2 diabetes who switched from another GLP-1 drug, long-term blood sugar fell over 24 months of once-weekly semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change, GLP-1RA-experienced participants
Study
n = 94
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
HbA1c change
−0.74%
GLP-1RA-experienced
Source sentences
Summary
After 24 months of follow-up, the reductions in HbA1c were -0.91 ± 0.7% (p<0.001) in the total cohort, -1.13 ± 1.38% (p<0.019) for GLP-1RA-naïve participants, and -0.74 ± 0.9% (p<0.023) for GLP-1RA-experienced participants.
1 context sentence(design, population, supporting numbers)
Summary · context
An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting.
Show in the study text Report a problemFND-3618712303
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes who had not used a GLP-1 receptor agonist, once-weekly semaglutide reduced HbA1c by 1.13% over 24 months.
In plain wordsIn adults with type 2 diabetes new to GLP-1 drugs, long-term blood sugar fell over 24 months of once-weekly semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change, GLP-1RA-naive participants
Study
n = 72
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
HbA1c change
−1.13%
GLP-1RA-naive
Source sentences
Summary
After 24 months of follow-up, the reductions in HbA1c were -0.91 ± 0.7% (p<0.001) in the total cohort, -1.13 ± 1.38% (p<0.019) for GLP-1RA-naïve participants, and -0.74 ± 0.9% (p<0.023) for GLP-1RA-experienced participants.
1 context sentence(design, population, supporting numbers)
Summary · context
An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting.
Show in the study text Report a problemFND-3618712302
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes on once-weekly semaglutide, 77.1% of the total cohort reached an HbA1c below 7%.
In plain wordsIn adults with type 2 diabetes on once-weekly semaglutide, 77.1% reached a long-term blood sugar level below 7%.
Peptide
Semaglutide
Outcome
Not applicableProportion reaching HbA1c below 7%
Study
n = 166
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Patients with HbA1c <7%
77.1%
total cohort
Source sentences
Summary
In the total cohort, 77.1% reached the objective of an HbA1c level <7%,
1 context sentence(design, population, supporting numbers)
Summary · context
An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting.
Show in the study text Report a problemFND-3618712306
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes on once-weekly semaglutide, 12.7% of the total cohort reached an HbA1c between 7.1% and 7.5%.
In plain wordsIn adults with type 2 diabetes on once-weekly semaglutide, 12.7% reached a long-term blood sugar level between 7.1% and 7.5%.
Peptide
Semaglutide
Outcome
Not applicableProportion reaching HbA1c between 7.1% and 7.5%
Study
n = 166
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Patients with HbA1c 7.1-7.5%
12.7%
total cohort
Source sentences
Summary
and 12.7% reached between 7.1% and 7.5%.
1 context sentence(design, population, supporting numbers)
Summary · context
An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting.
Show in the study text Report a problemFND-3618712307
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes on once-weekly semaglutide, 66.9% achieved a weight reduction of 5% or more.
In plain wordsIn adults with type 2 diabetes on once-weekly semaglutide, 66.9% lost at least 5% of their body weight.
Peptide
Semaglutide
Outcome
Not applicableProportion with weight reduction of 5% or more
Study
n = 166
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Patients with weight reduction >=5%
66.9%
total cohort
Source sentences
Summary
Additionally, 66.9% achieved a weight reduction ≥5%.
1 context sentence(design, population, supporting numbers)
Summary · context
An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting.
Show in the study text Report a problemFND-3618712308
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes who switched from another GLP-1 receptor agonist, once-weekly semaglutide reduced body weight by 7.65%, less than in GLP-1RA-naive participants.
In plain wordsIn adults with type 2 diabetes who switched from another GLP-1 drug, semaglutide lowered body weight less than in people new to GLP-1 drugs.
Peptide
Semaglutide
Outcome
DecreaseBody weight change, GLP-1RA-experienced participants
Study
n = 94
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Body weight change
−7.65%
GLP-1RA-experienced
Source sentences
Summary
Body weight reductions were -12.42 ± 9.1% in GLP-1RA-naïve participants vs. -7.65 ± 9.7% in GLP-1RA-experienced participants (p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting.
Show in the study text Report a problemFND-3618712305
08HumanObservational studyEfficacy outcome
In adults with type 2 diabetes who had not used a GLP-1 receptor agonist, once-weekly semaglutide reduced body weight by 12.42%, more than in GLP-1RA-experienced participants.
In plain wordsIn adults with type 2 diabetes new to GLP-1 drugs, semaglutide lowered body weight more than in people who had used GLP-1 drugs before.
Peptide
Semaglutide
Outcome
DecreaseBody weight change, GLP-1RA-naive participants
Study
n = 72
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Body weight change
−12.42%
GLP-1RA-naive
Source sentences
Summary
Body weight reductions were -12.42 ± 9.1% in GLP-1RA-naïve participants vs. -7.65 ± 9.7% in GLP-1RA-experienced participants (p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting.
Show in the study text Report a problemFND-3618712304
09HumanObservational studySafety outcome
In adults with type 2 diabetes, adverse events with once-weekly semaglutide were consistent with its known safety profile.
In plain wordsIn adults with type 2 diabetes, side effects of once-weekly semaglutide matched what is already known about the drug.
Peptide
Semaglutide
Outcome
Not applicableAdverse events
Study
n = 166
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
The reported adverse events were consistent with the known safety profile of semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting.
Show in the study text Report a problemFND-3618712309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT06426446

Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data

Assistance Publique - Hôpitaux de Parisn = 80est. 1 Jun 2024 to est. 1 Jun 2025

Obesity

Trial page ClinicalTrials.govUpdated 23 May 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.